NEW YORK (GenomeWeb News) – Wake Forest University and spin-out company NanoMedica have received $860,000 in funding to move a bead-based genetic sequencing drug discovery technology closer to commercialization, Wake Forest said today.

The funding includes a $700,000 Small Business Innovation Research award from the National Institutes of Health and a $160,000 grant from the North Carolina Biotechnology Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.